BIO vs WAT

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

BIO

59.1
AI Score
VS
BIO Wins

WAT

53.3
AI Score

Investment Advisor Scores

BIO

59score
Recommendation
HOLD

WAT

53score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric BIO WAT Winner
Revenue 1.90B 4.68B WAT
Net Income 302.90M -127.00M BIO
Net Margin 15.9% -2.7% BIO
Operating Income 57.00M -6.00M BIO
ROE 4.0% -0.8% BIO
ROA 2.8% -0.5% BIO
Total Assets 10.78B 24.11B WAT
Cash 465.30M 593.00M WAT
Debt/Equity 0.16 0.29 BIO
Current Ratio 3.18 1.89 BIO

Relative Price Performance (Last 90 Days)

BIO 1M: +6.1% · 3M: +6.7% WAT 1M: +10.0% · 3M: +14.3%

Current Technical Phase

BIO

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (0.6% over 20 days), RSI 58

RSI (14): 58.2 · Price: $386.48

WAT

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (4.5% over 20 days), RSI 61

RSI (14): 61.0 · Price: $475.52

Fundamentals Snapshot

Metric BIO WAT
Market Cap — —
Forward P/E 39.0 28.8
Trailing P/E 10.3 199.5
Revenue (TTM) — —
Revenue Growth 0.0% 1.2%
Gross Margin 0.5% 0.5%
Operating Margin 0.1% 0.1%
EPS 37.64 2.39
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, BIO is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.